Ivermectin increases striatal cholinergic activity to facilitate dopamine terminal function

• Published in: Cell & bioscience 2024-04, Vol.14 (1), p.50-50, Article 50
• Main Authors: Wadsworth, Hillary A, Warnecke, Alicia M P, Barlow, Joshua C, Robinson, J Kayden, Steimle, Emma, Ronström, Joakim W, Williams, Pacen E, Galbraith, Christopher J, Baldridge, Jared, Jakowec, Michael W, Davies, Daryl L, Yorgason, Jordan T
• Format: Article
• Language: English
• Subjects: FSCV; Ivermectin; Parkinson’s; Purinergic P2X4 receptors; Receptors
• ISSN: 2045-3701; 2045-3701
• DOI: 10.1186/s13578-024-01228-2

Ivermectin (IVM) is a commonly prescribed antiparasitic treatment with pharmacological effects on invertebrate glutamate ion channels resulting in paralysis and death of invertebrates. However, it can also act as a modulator of some vertebrate ion channels and has shown promise in facilitating L-DOPA treatment in preclinical models of Parkinson's disease. The pharmacological effects of IVM on dopamine terminal function were tested, focusing on the role of two of IVM's potential targets: purinergic P2X4 and nicotinic acetylcholine receptors. Ivermectin enhanced electrochemical detection of dorsal striatum dopamine release. Although striatal P2X4 receptors were observed, IVM effects on dopamine release were not blocked by P2X4 receptor inactivation. In contrast, IVM attenuated nicotine effects on dopamine release, and antagonizing nicotinic receptors prevented IVM effects on dopamine release. IVM also enhanced striatal cholinergic interneuron firing. L-DOPA enhances dopamine release by increasing vesicular content. L-DOPA and IVM co-application further enhanced release but resulted in a reduction in the ratio between high and low frequency stimulations, suggesting that IVM is enhancing release largely through changes in terminal excitability and not vesicular content. Thus, IVM is increasing striatal dopamine release through enhanced cholinergic activity on dopamine terminals.